scPharma Q2 net FUROSCIX rev $16M (+99% YoY); 20,200 doses shipped (+117%)

scPharmaceuticals Inc.

2025-Q2 EPS reported -$0.70 revenue$27,793,000

Net FUROSCIX revenue $16.0M vs $8.1M in Q2 2024; doses shipped ~20,200 (up 117% YoY).
Net loss of $18.0M for Q2 2025 vs $17.1M in Q2 2024; cash & equivalents $40.8M at June 30.
Launched FUROSCIX for CKD edema in late April; nephrologist prescriptions beginning.
Autoinjector (SCP-111) sNDA filing on track for Q3 2025; reduces infusion time to <10 seconds.
CMS proposed Ambulatory Specialty Model may benefit FUROSCIX uptake for heart failure management.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.